The University of Iowa
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us


8798 John Pappajohn Pavilion
Iowa City IA 52242
(319) 356-7123

Release: July 22, 1999

UI study evaluates drug to prevent recurrence of stroke

IOWA CITY, Iowa -- Patients who have had stroke, transient ischemic attack, or both peripheral vascular disease and stroke are invited to participate in a University of Iowa Health Care study evaluating a drug that might prevent recurrence of further vascular disease.

The trial -- called Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO) -- will evaluate whether the anti-platelet drug, lotrafiban, taken in combination with aspirin, will reduce the occurrence of death, stroke, heart attack or revascularization surgery. Lotrafiban prevents excessive blood clot formation in patients experiencing the onset of stroke or other vascular disease.

"Half the participants in BRAVO will receive the drug with aspirin and half will receive a placebo with aspirin," said Patricia Davis, M.D., UI associate professor of neurology. "It's a double-blind study, which means participants will not know whether they are receiving the drug or receiving the placebo."

Davis, who is principal investigator of the UI Health Care portion of the international trial, said participants will be followed for two years, with a visit to the UI Hospitals and Clinics required once every three months.

There is no cost for the drug or for any trial-related patient visits during the study.

To qualify, stroke patients must have experienced stroke or transient ischemic attack within 30 days before enrollment. There is no such limit for patients with a history of stroke and peripheral vascular disease.

The trial's coordinator is Lynn Vining.

For more information about enrolling in the study, patients should call UI Health Access at (319) 384-4442 or toll-free, (800) 777-8442. Physicians are encouraged to call UI Consult at
(319) 384-8008 or toll-free, (800) 322-8442.